Literature DB >> 29212855

T-Cell Densities in Brain Metastases Are Associated with Patient Survival Times and Diffusion Tensor MRI Changes.

Rasheed Zakaria1,2, Angela Platt-Higgins2, Nitika Rathi3, Mark Radon4, Sumit Das3, Kumar Das4, Maneesh Bhojak4, Andrew Brodbelt5, Emmanuel Chavredakis5, Michael D Jenkinson5,6, Philip S Rudland2.   

Abstract

Brain metastases are common and are usually detected by MRI. Diffusion tensor imaging (DTI) is a derivative MRI technique that can detect disruption of white matter tracts in the brain. We have matched preoperative DTI with image-guided sampling of the brain-tumor interface in 26 patients during resection of a brain metastasis and assessed mean diffusivity and fractional anisotropy (FA). The tissue samples were analyzed for vascularity, inflammatory cell infiltration, growth pattern, and tumor expression of proteins associated with growth or local invasion such as Ki67, S100A4, and MMP2, 9, and 13. A lower FA in the peritumoral region indicated more white matter tract disruption and independently predicted longer overall survival times (HR for death = 0.21; 95% confidence interval, 0.06-0.82; P = 0.024). Of all the biological markers studied, only increased density of CD3+ lymphocytes in the same region correlated with decreased FA (Mann-Whitney U, P = 0.037) as well as confounding completely the effect of FA on multivariate survival analyses. We conclude that the T-cell response to brain metastases is not a surrogate of local tumor invasion, primary cancer type, or aggressive phenotype and is associated with patient survival time regardless of these biological factors. Furthermore, it can be assayed by DTI, potentially offering a quick, noninvasive, clinically available method to detect an active immune microenvironment and, in principle, to measure susceptibility to immunotherapy.Significance: These findings show that white matter tract integrity is degraded in areas where T-cell infiltration is highest, providing a noninvasive method to identify immunologically active microenvironments in secondary brain tumors. Cancer Res; 78(3); 610-6. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 29212855      PMCID: PMC5796648          DOI: 10.1158/0008-5472.CAN-17-1720

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  A pathology-based substrate for target definition in radiosurgery of brain metastases.

Authors:  Brigitta G Baumert; Isabelle Rutten; Cary Dehing-Oberije; Albert Twijnstra; Miranda J M Dirx; Ria M T L Debougnoux-Huppertz; Philippe Lambin; Bela Kubat
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-11       Impact factor: 7.038

2.  Incidence of local in-brain progression after supramarginal resection of cerebral metastases.

Authors:  Marcel A Kamp; Marion Rapp; Philipp J Slotty; Bernd Turowski; Hosai Sadat; Maria Smuga; Maxine Dibué-Adjei; Hans-Jakob Steiger; Andrea Szelényi; Michael Sabel
Journal:  Acta Neurochir (Wien)       Date:  2015-04-07       Impact factor: 2.216

Review 3.  Response assessment criteria for brain metastases: proposal from the RANO group.

Authors:  Nancy U Lin; Eudocia Q Lee; Hidefumi Aoyama; Igor J Barani; Daniel P Barboriak; Brigitta G Baumert; Martin Bendszus; Paul D Brown; D Ross Camidge; Susan M Chang; Janet Dancey; Elisabeth G E de Vries; Laurie E Gaspar; Gordon J Harris; F Stephen Hodi; Steven N Kalkanis; Mark E Linskey; David R Macdonald; Kim Margolin; Minesh P Mehta; David Schiff; Riccardo Soffietti; John H Suh; Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen
Journal:  Lancet Oncol       Date:  2015-05-27       Impact factor: 41.316

4.  Characterization of the inflammatory response to solid cancer metastases in the human brain.

Authors:  Anna Sophie Berghoff; Hans Lassmann; Matthias Preusser; Romana Höftberger
Journal:  Clin Exp Metastasis       Date:  2012-07-01       Impact factor: 5.150

5.  Metastasis-inducing proteins are widely expressed in human brain metastases and associated with intracranial progression and radiation response.

Authors:  Rasheed Zakaria; Angela Platt-Higgins; Nitika Rathi; Daniel Crooks; Andrew Brodbelt; Emmanuel Chavredakis; David Lawson; Michael D Jenkinson; Philip S Rudland
Journal:  Br J Cancer       Date:  2016-04-21       Impact factor: 7.640

6.  Reduced local recurrence of a single brain metastasis through microscopic total resection.

Authors:  Heon Yoo; Young Zoon Kim; Byung Ho Nam; Sang Hoon Shin; Hee Seok Yang; Jin Soo Lee; Jae Il Zo; Seung Hoon Lee
Journal:  J Neurosurg       Date:  2009-04       Impact factor: 5.115

7.  Structural and functional effects of metastases in rat brain determined by multimodal MRI.

Authors:  Sébastien Serres; Christopher J Martin; Manuel Sarmiento Soto; Claire Bristow; Emma R O'Brien; John J Connell; Alexandre A Khrapitchev; Nicola R Sibson
Journal:  Int J Cancer       Date:  2013-08-29       Impact factor: 7.396

8.  Multi-centre reproducibility of diffusion MRI parameters for clinical sequences in the brain.

Authors:  Matthew Grech-Sollars; Patrick W Hales; Keiko Miyazaki; Felix Raschke; Daniel Rodriguez; Martin Wilson; Simrandip K Gill; Tina Banks; Dawn E Saunders; Jonathan D Clayden; Matt N Gwilliam; Thomas R Barrick; Paul S Morgan; Nigel P Davies; James Rossiter; Dorothee P Auer; Richard Grundy; Martin O Leach; Franklyn A Howe; Andrew C Peet; Chris A Clark
Journal:  NMR Biomed       Date:  2015-04       Impact factor: 4.044

9.  The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study.

Authors:  Laila Siam; Annalen Bleckmann; Han-Ning Chaung; Alexander Mohr; Florian Klemm; Alonso Barrantes-Freer; Raquel Blazquez; Hendrik A Wolff; Florian Lüke; Veit Rohde; Christine Stadelmann; Tobias Pukrop
Journal:  Oncotarget       Date:  2015-10-06

Review 10.  Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Authors:  Sacha Gnjatic; Vincenzo Bronte; Laura Rosa Brunet; Marcus O Butler; Mary L Disis; Jérôme Galon; Leif G Hakansson; Brent A Hanks; Vaios Karanikas; Samir N Khleif; John M Kirkwood; Lance D Miller; Dolores J Schendel; Isabelle Tanneau; Jon M Wigginton; Lisa H Butterfield
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751

View more
  15 in total

Review 1.  Clinical correlates for immune checkpoint therapy: significance for CNS malignancies.

Authors:  Nivedita M Ratnam; Stephen C Frederico; Javier A Gonzalez; Mark R Gilbert
Journal:  Neurooncol Adv       Date:  2020-11-27

Review 2.  Emerging principles of brain immunology and immune checkpoint blockade in brain metastases.

Authors:  Jawad Fares; Ilya Ulasov; Peter Timashev; Maciej S Lesniak
Journal:  Brain       Date:  2021-05-07       Impact factor: 13.501

Review 3.  Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis.

Authors:  Michael Schulz; Anna Salamero-Boix; Katja Niesel; Tijna Alekseeva; Lisa Sevenich
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

Review 4.  Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease.

Authors:  Suneel D Kamath; Priya U Kumthekar
Journal:  Front Oncol       Date:  2018-09-27       Impact factor: 6.244

5.  The Potential of Astrocytes as Immune Modulators in Brain Tumors.

Authors:  Neibla Priego; Manuel Valiente
Journal:  Front Immunol       Date:  2019-06-11       Impact factor: 7.561

Review 6.  Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence.

Authors:  Mathieu Sinigaglia; Tarek Assi; Florent L Besson; Samy Ammari; Myriam Edjlali; Whitney Feltus; Laura Rozenblum-Beddok; Binsheng Zhao; Lawrence H Schwartz; Fatima-Zohra Mokrane; Laurent Dercle
Journal:  EJNMMI Res       Date:  2019-08-20       Impact factor: 3.138

Review 7.  Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.

Authors:  Benjamin B Kasten; Neha Udayakumar; Jianmei W Leavenworth; Anna M Wu; Suzanne E Lapi; Jonathan E McConathy; Anna G Sorace; Asim K Bag; James M Markert; Jason M Warram
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

Review 8.  Brain Metastasis Organotropism.

Authors:  Arseniy E Yuzhalin; Dihua Yu
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915

9.  Management evaluation of metastasis in the brain (MEMBRAIN)-a United Kingdom and Ireland prospective, multicenter observational study.

Authors:  Josephine Jung; Jignesh Tailor; Emma Dalton; Laurence J Glancz; Joy Roach; Rasheed Zakaria; Simon Lammy; Aswin Chari; Karol P Budohoski; Laurent J Livermore; Kenny Yu; Michael D Jenkinson; Paul M Brennan; Lucy Brazil; Catey Bunce; Elli Bourmpaki; Keyoumars Ashkan; Francesco Vergani
Journal:  Neurooncol Pract       Date:  2019-12-06

Review 10.  Next-generation immunotherapies for brain metastatic cancers.

Authors:  María López Vázquez; Wanlu Du; Nobuhiko Kanaya; Yohei Kitamura; Khalid Shah
Journal:  Trends Cancer       Date:  2021-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.